Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.

Trial Details

NCT ID
NCT06520176
Phase
PHASE3
Sponsor
The Affiliated People's Hospital of Ningbo University
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Etoposide
  • Cytarabine
  • Pegfilgrastim
  • Cyclophosphamide
  • G-CSF
Locations (sample)
  • Dongyang, Zhejiang, China|29.26778,120.22528
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Huzhou, Zhejiang, China|30.8703,120.0933
  • Jiaxing, Zhejiang, China|30.7522,120.75

Key Eligibility Criteria

  • 1\. Patients newly diagnosed as multiple myeloma.
  • 2\. Indication for ASCT.
  • 3\. Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1.
  • 4\. Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →